OxyContin has fueled the opioid crisis in Canada for many years. Purdue Pharma created OxyContin and made billons off of it while falsely promoting it as a less addictive opioid. In 2007, Purdue pled guilty in the U.S. to misleading regulators and doctors regarding the risks of OxyContin. Even after pleading guilty, Purdue continue to promote the sale and prescriptions of OxyContin, making profit on the opioid crisis.
Purdue has now declared bankruptcy while simultaneously facing billions of dollars in potential lawsuits. As part of the bankruptcy process in the U.S., Purdue has now settled all litigation, which includes a release for Purdue and the Sackler family which owned Purdue. Purdue has been able to avoid litigation as a result of its bankruptcy.
In Canada, lawsuits on behalf of individuals and provinces regarding opioids are winding through provincial legal systems. The Canadian litigation is seeking compensation for provincial health care systems and individuals who suffered harm from opioids. The Canadian cases naming Purdue are now subject to the bankruptcy of Purdue and will not proceed.
Goldblatt Partners and Sotos LLP are considering a potential class action against defendants not named in the current OxyContin lawsuits concerning Purdue. These law firms are seeking to speak to any individual who took OxyContin at any time from 2007 to the present and developed a dependency to any opioid. The law firms are seeking to bring a class action for the harm from the opioid epidemic and looking for someone who would be willing to be a representative plaintiff.
A representative plaintiff is someone who is a voice for a group of people in a similar position. We are looking to speak with anyone who is willing to be a representative plaintiff for people who took OxyContin. The representative plaintiff would commence a lawsuit regarding the dangerous promotion and sale of OxyContin with the help of the class action law firms.
Anyone who wishes to speak to these law firms about a potential class action regarding OxyContin should contact Jody Brown. Jody will respond to text messages and accepts collect calls.
Jody Brown (he/him)
Goldblatt Partners
416-453-9050 (cell)
JBrown@goldblattpartners.com